Lipocine (LPCN) Competitors $3.15 -0.01 (-0.32%) Closing price 03:59 PM EasternExtended Trading$3.24 +0.09 (+2.86%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPCN vs. NRXP, GNTA, KPTI, ICCC, CUE, INMB, ACRV, ATNM, FGEN, and BRNSShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include NRx Pharmaceuticals (NRXP), Genenta Science (GNTA), Karyopharm Therapeutics (KPTI), ImmuCell (ICCC), Cue Biopharma (CUE), INmune Bio (INMB), Acrivon Therapeutics (ACRV), Actinium Pharmaceuticals (ATNM), FibroGen (FGEN), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry. Lipocine vs. Its Competitors NRx Pharmaceuticals Genenta Science Karyopharm Therapeutics ImmuCell Cue Biopharma INmune Bio Acrivon Therapeutics Actinium Pharmaceuticals FibroGen Barinthus Biotherapeutics NRx Pharmaceuticals (NASDAQ:NRXP) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Do analysts recommend NRXP or LPCN? NRx Pharmaceuticals presently has a consensus target price of $34.50, suggesting a potential upside of 869.10%. Lipocine has a consensus target price of $8.00, suggesting a potential upside of 153.97%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71Lipocine 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Do insiders & institutionals hold more shares of NRXP or LPCN? 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 19.0% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable valuation and earnings, NRXP or LPCN? Lipocine has higher revenue and earnings than NRx Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNRx PharmaceuticalsN/AN/A-$25.13M-$2.24-1.59Lipocine$11.20M1.52$10K-$0.87-3.62 Which has more volatility and risk, NRXP or LPCN? NRx Pharmaceuticals has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Does the media refer more to NRXP or LPCN? In the previous week, NRx Pharmaceuticals had 4 more articles in the media than Lipocine. MarketBeat recorded 6 mentions for NRx Pharmaceuticals and 2 mentions for Lipocine. Lipocine's average media sentiment score of 0.95 beat NRx Pharmaceuticals' score of 0.68 indicating that Lipocine is being referred to more favorably in the news media. Company Overall Sentiment NRx Pharmaceuticals Positive Lipocine Positive Is NRXP or LPCN more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat Lipocine's return on equity.Company Net Margins Return on Equity Return on Assets NRx PharmaceuticalsN/A N/A -550.94% Lipocine N/A -23.59%-21.91% SummaryNRx Pharmaceuticals beats Lipocine on 8 of the 14 factors compared between the two stocks. Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.12M$2.65B$6.14B$10.65BDividend YieldN/A56.72%5.66%4.70%P/E Ratio-3.6223.7585.8427.65Price / Sales1.52782.57621.60138.35Price / CashN/A177.3038.3262.20Price / Book0.805.6413.066.79Net Income$10K$32.78M$3.30B$275.88M7 Day Performance1.94%6.31%4.81%2.64%1 Month Performance9.76%13.80%9.99%9.13%1 Year Performance-39.07%2.75%85.28%35.89% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine3.1596 of 5 stars$3.15-0.3%$8.00+154.0%-40.4%$17.12M$11.20M-3.6210Analyst ForecastNRXPNRx Pharmaceuticals3.1487 of 5 stars$3.25+10.2%$34.50+961.5%+141.9%$58.44MN/A-1.452Analyst ForecastGNTAGenenta Science0.9523 of 5 stars$3.18+0.6%$25.00+686.2%-37.6%$57.80MN/A0.007News CoveragePositive NewsAnalyst ForecastKPTIKaryopharm Therapeutics3.9216 of 5 stars$6.35-3.1%$34.00+435.4%-53.3%$56.80M$145.24M-0.44380Trending NewsAnalyst ForecastGap DownICCCImmuCell1.169 of 5 stars$6.18+2.5%N/A+80.1%$54.55M$26.49M32.5370News CoveragePositive NewsAnalyst ForecastGap DownHigh Trading VolumeCUECue Biopharma2.6694 of 5 stars$0.72+1.3%N/A-30.2%$54.54M$9.29M-1.2860News CoveragePositive NewsShort Interest ↓High Trading VolumeINMBINmune Bio3.0544 of 5 stars$2.11+5.0%$18.50+776.8%-62.1%$53.44M$10K-0.8510News CoveragePositive NewsAnalyst ForecastGap UpACRVAcrivon Therapeutics2.9771 of 5 stars$1.82+9.6%$15.00+724.2%-73.1%$52.22MN/A-0.8158News CoveragePositive NewsAnalyst ForecastATNMActinium Pharmaceuticals1.9754 of 5 stars$1.62+0.6%$4.50+177.8%-5.5%$50.54MN/A-1.1730FGENFibroGen4.3185 of 5 stars$12.31flat$43.00+249.3%+38.9%$49.78M$29.62M-32.39570News CoverageAnalyst ForecastBRNSBarinthus Biotherapeutics2.5386 of 5 stars$1.48+21.3%$3.00+102.7%+25.3%$49.68M$14.97M-0.86107Positive NewsHigh Trading Volume Related Companies and Tools Related Companies NRXP Alternatives GNTA Alternatives KPTI Alternatives ICCC Alternatives CUE Alternatives INMB Alternatives ACRV Alternatives ATNM Alternatives FGEN Alternatives BRNS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPCN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
